MedTrace Logo

Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)

NCT01216371 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2012-02-13

No results posted yet for this study

Summary

The aim ist to identify biomarkers in the blood, to indicate early response or early treatment resistance.

Conditions

Interventions

DRUG

Sunitinib

one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break

DRUG

Placebo

one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,

Sponsors & Collaborators

  • University Hospital, Essen

    collaborator OTHER

  • Association of Urologic Oncology (AUO)

    lead OTHER

Principal Investigators

  • Susanne Krege, Priv. Doz. Dr. med. · urological hospital of Maria Hilf Krankenhaus Krefeld

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2015-10-31
Completion
2015-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01216371 on ClinicalTrials.gov